Works matching IS 20445385 AND DT 2023 AND VI 13 AND IP 1

Results: 252
    1
    2

    Zanubrutinib: past, present, and future.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00902-x
    By:
    • Tam, Constantine S.;
    • Muñoz, Javier L.;
    • Seymour, John F.;
    • Opat, Stephen
    Publication type:
    Article
    3

    Correction: Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

    Published in:
    2023
    By:
    • Martin, Thomas;
    • Dimopoulos, Meletios-Athanasios;
    • Mikhael, Joseph;
    • Yong, Kwee;
    • Capra, Marcelo;
    • Facon, Thierry;
    • Hajek, Roman;
    • Špička, Ivan;
    • Baker, Ross;
    • Kim, Kihyun;
    • Martinez, Gracia;
    • Min, Chang-Ki;
    • Pour, Ludek;
    • Leleu, Xavier;
    • Oriol, Albert;
    • Koh, Youngil;
    • Suzuki, Kenshi;
    • Casca, France;
    • Macé, Sandrine;
    • Risse, Marie-Laure
    Publication type:
    Correction Notice
    4

    Clinical characteristics and outcomes in risk-stratified patients with smoldering multiple myeloma: data from the Czech Republic Registry of Monoclonal Gammopathies.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00906-7
    By:
    • Sandecka, Viera;
    • Popkova, Tereza;
    • Stork, Martin;
    • Maisnar, Vladimir;
    • Minarik, Jiri;
    • Jungova, Alexandra;
    • Pavlicek, Petr;
    • Stejskal, Lukas;
    • Pospisilova, Lenka;
    • Heindorfer, Adriana;
    • Obernauerova, Jarmila;
    • Gregora, Evzen;
    • Sykora, Michal;
    • Ullrychova, Jana;
    • Wrobel, Marek;
    • Kessler, Petr;
    • Jelinek, Tomas;
    • Kunovszki, Peter;
    • Bathija, Sacheeta;
    • Gros, Blanca
    Publication type:
    Article
    5

    Isatuximab, carfilzomib, and dexamethasone in patients with relapsed multiple myeloma: updated results from IKEMA, a randomized Phase 3 study.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00797-8
    By:
    • Martin, Thomas;
    • Dimopoulos, Meletios-Athanasios;
    • Mikhael, Joseph;
    • Yong, Kwee;
    • Capra, Marcelo;
    • Facon, Thierry;
    • Hajek, Roman;
    • Špička, Ivan;
    • Baker, Ross;
    • Kim, Kihyun;
    • Martinez, Gracia;
    • Min, Chang-Ki;
    • Pour, Ludek;
    • Leleu, Xavier;
    • Oriol, Albert;
    • Koh, Youngil;
    • Suzuki, Kenshi;
    • Casca, France;
    • Macé, Sandrine;
    • Risse, Marie-Laure
    Publication type:
    Article
    6

    Late effects in survivors of infant acute lymphoblastic leukaemia—a study of the Australian and New Zealand Children's Haematology/Oncology Group.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00924-5
    By:
    • Mironova, Denitza;
    • Saraswati, Chitra M.;
    • Downie, Peter;
    • Lai, Chow Yee;
    • Cook, Eleanor;
    • Carruthers, Vickyanne;
    • Moukhaiber, Perla;
    • Molloy, Fiona;
    • Serov, Joshua;
    • McKinnon, Elizabeth;
    • Alvaro, Frank;
    • Osborn, Michael;
    • Revesz, Tamas;
    • Prestidge, Tim;
    • Cross, Siobhan;
    • Bateman, Caroline M.;
    • Moore, Andrew S.;
    • Khaw, Seong Lin;
    • Mateos, Marion K.;
    • Kotecha, Rishi S.
    Publication type:
    Article
    7
    8

    U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00922-7
    By:
    • Badar, Talha;
    • Vanegas, Yenny A. Moreno;
    • Nanaa, Ahmad;
    • Foran, James M.;
    • Al-Kali, Aref;
    • Mangaonkar, Abhishek;
    • Murthy, Hemant;
    • Alkhateeb, Hassan B.;
    • Viswanatha, David;
    • He, Rong;
    • Shah, Mithun;
    • Yi, Cecilia Arana;
    • Litzow, Mark R.;
    • Gangat, Naseema;
    • Tefferi, Ayalew;
    • Patnaik, Mrinal M.
    Publication type:
    Article
    9

    Response patterns and impact of MRD in patients with IDH1/2-mutated AML treated with venetoclax and hypomethylating agents.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00915-6
    By:
    • Hammond, Danielle;
    • Loghavi, Sanam;
    • Wang, Sa A.;
    • Konopleva, Marina Y.;
    • Kadia, Tapan M.;
    • Daver, Naval G.;
    • Ohanian, Maro;
    • Issa, Ghayas C.;
    • Alvarado, Yesid;
    • Short, Nicholas J.;
    • Sasaki, Koji;
    • Pemmaraju, Naveen;
    • Montalban-Bravo, Guillermo;
    • Lachowiez, Curtis A.;
    • Maiti, Abhishek;
    • Garcia-Manero, Guillermo;
    • Jabbour, Elias J.;
    • Borthakur, Gautam;
    • Ravandi, Farhad;
    • Takahashi, Koichi
    Publication type:
    Article
    10
    11
    12
    13
    14
    15
    16
    17

    Zanubrutinib: past, present, and future.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00902-x
    By:
    • Tam, Constantine S.;
    • Muñoz, Javier L.;
    • Seymour, John F.;
    • Opat, Stephen
    Publication type:
    Article
    18
    19

    Prospective evaluation of genome sequencing to compare conventional cytogenetics in acute myeloid leukemia.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00908-5
    By:
    • Pitel, Beth A.;
    • Zepeda-Mendoza, Cinthya;
    • Sachs, Zohar;
    • Tang, Hongwei;
    • Shivaram, Suganti;
    • Sharma, Neeraj;
    • Smadbeck, James B.;
    • Smoley, Stephanie A.;
    • Pearce, Kathryn E.;
    • Luoma, Ivy M.;
    • Cook, Joselle;
    • Litzow, Mark R.;
    • Hoppman, Nicole L.;
    • Viswanatha, David;
    • Xu, Xinjie;
    • Ketterling, Rhett P.;
    • Greipp, Patricia T.;
    • Peterson, Jess F.;
    • Baughn, Linda B.
    Publication type:
    Article
    20
    21

    Gemtuzumab ozogamicin plus standard induction chemotherapy improves outcomes of newly diagnosed intermediate cytogenetic risk acute myeloid leukemia.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00910-x
    By:
    • Awada, Hassan;
    • Abdelmalek, Mina;
    • Cronin, Tara;
    • Baron, Jeffrey;
    • Kashour, Zakariya;
    • Azad, Farhan;
    • Faisal, Muhammad Salman;
    • Faber, Mark;
    • Gravina, Matthew;
    • Sung, Pamela J.;
    • Green, Steven D.;
    • Przespolewski, Amanda;
    • Thompson, James E.;
    • Griffiths, Elizabeth A.;
    • Wang, Eunice S.
    Publication type:
    Article
    22
    23

    Correction: Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00888-6
    By:
    • McCurdy, Arleigh;
    • Mian, Hira;
    • LeBlanc, Richard;
    • Jimenez-Zepeda, Victor H.;
    • Su, Jiandong;
    • Masih-Khan, Esther;
    • Visram, Alissa;
    • Louzada, Martha;
    • Song, Kevin;
    • White, Darrell;
    • Sebag, Michael;
    • Stakiw, Julie;
    • Reiman, Anthony;
    • Aslam, Muhammad;
    • Bergstrom, Debra;
    • Kotb, Rami;
    • Kaedbey, Rayan;
    • Gul, Engin;
    • Reece, Donna;
    • Venner, Christopher P.
    Publication type:
    Article
    24
    25

    Long-term outcomes of allogeneic stem cell transplant in multiple myeloma.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00900-z
    By:
    • Schmidt, Walker M.;
    • Perera, Nirosha D.;
    • Buadi, Francis K.;
    • Hayman, Suzanne R.;
    • Kumar, Shaji K.;
    • Dispenzieri, Angela;
    • Dingli, David;
    • Cook, Joselle;
    • Lacy, Martha Q.;
    • Kapoor, Prashant;
    • Leung, Nelson;
    • Muchtar, Eli;
    • Warsame, Rahma M.;
    • Kourelis, Taxiarchis;
    • Binder, Moritz;
    • Gonsalves, Wilson I.;
    • Hogan, William J.;
    • Gertz, Morie A.
    Publication type:
    Article
    26

    T-cell phenotype including CD57<sup>+</sup> T follicular helper cells in the tumor microenvironment correlate with a poor outcome in follicular lymphoma.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00899-3
    By:
    • Yang, Zhi-Zhang;
    • Kim, Hyo Jin;
    • Wu, Hongyan;
    • Tang, Xinyi;
    • Yu, Yue;
    • Krull, Jordan;
    • Larson, Daniel P.;
    • Moore, Raymond M.;
    • Maurer, Matthew J.;
    • Pavelko, Kevin D.;
    • Jalali, Shahrzad;
    • Pritchett, Joshua C.;
    • Mudappathi, Rekha;
    • Wang, Junwen;
    • Villasboas, Jose C.;
    • Mondello, Patrizia;
    • Novak, Anne J.;
    • Ansell, Stephen M.
    Publication type:
    Article
    27
    28

    Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00895-7
    By:
    • Breen, William G.;
    • Young, Jason R.;
    • Hathcock, Matthew A.;
    • Kowalchuk, Roman O.;
    • Thorpe, Matthew P.;
    • Bansal, Radhika;
    • Khurana, Arushi;
    • Bennani, N. Nora;
    • Paludo, Jonas;
    • Bisneto, Jose Villasboas;
    • Wang, Yucai;
    • Ansell, Stephen M.;
    • Peterson, Jennifer L.;
    • Johnston, Patrick B.;
    • Lester, Scott C.;
    • Lin, Yi
    Publication type:
    Article
    29
    30

    Real-world experience with ponatinib therapy in chronic phase chronic myeloid leukemia: impact of depth of response on survival and prior exposure to nilotinib on arterial occlusive events.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00891-x
    By:
    • Abdelmagid, Maymona G.;
    • Al-Kali, Aref;
    • Litzow, Mark R.;
    • Begna, Kebede H.;
    • Hogan, William J.;
    • Patnaik, Mirinal S.;
    • Hashmi, Shahrukh K.;
    • Elliott, Michelle A.;
    • Alkhateeb, Hassan;
    • Karrar, Omer S.;
    • Fleti, Farah;
    • Elnayir, Mohammed H.;
    • Rivera, Candido E.;
    • Murthy, Hemant S.;
    • Foran, James M.;
    • Kharfan-Dabaja, Mohamed A.;
    • Badar, Talha;
    • Viswanatha, David S.;
    • Reichard, Kaaren K.;
    • Gangat, Naseema
    Publication type:
    Article
    31

    Validation of the molecular international prognostic scoring system in patients with myelodysplastic syndromes defined by international consensus classification.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00894-8
    By:
    • Lee, Wan-Hsuan;
    • Tsai, Ming-Tao;
    • Tsai, Cheng-Hong;
    • Tien, Feng-Ming;
    • Lo, Min-Yen;
    • Tseng, Mei-Hsuan;
    • Kuo, Yuan-Yeh;
    • Liu, Ming-Chih;
    • Yang, Yi-Tsung;
    • Chen, Jui-Che;
    • Tang, Jih-Luh;
    • Sun, Hsun-I;
    • Chuang, Yi-Kuang;
    • Lin, Liang-In;
    • Chou, Wen-Chien;
    • Lin, Chien-Chin;
    • Hou, Hsin-An;
    • Tien, Hwei-Fang
    Publication type:
    Article
    32
    33
    34

    Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00890-y
    By:
    • Miao, Yi;
    • Sha, Yeqin;
    • Xia, Yi;
    • Qin, Shuchao;
    • Jiang, Rui;
    • Dai, Luomengjia;
    • Shen, Hui;
    • Qiu, Tonglu;
    • Wu, Wei;
    • Qiu, Jingyan;
    • Yang, Yilian;
    • Ding, Chongyang;
    • Wu, Yujie;
    • Fan, Lei;
    • Xu, Wei;
    • Li, Jianyong;
    • Zhu, Huayuan
    Publication type:
    Article
    35

    Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00886-8
    By:
    • Ferreri, Christopher J.;
    • Hildebrandt, Michelle A. T.;
    • Hashmi, Hamza;
    • Shune, Leyla O.;
    • McGuirk, Joseph P.;
    • Sborov, Douglas W.;
    • Wagner, Charlotte B.;
    • Kocoglu, M. Hakan;
    • Rapoport, Aaron;
    • Atrash, Shebli;
    • Voorhees, Peter M.;
    • Khouri, Jack;
    • Dima, Danai;
    • Afrough, Aimaz;
    • Kaur, Gurbakhash;
    • Anderson Jr., Larry D.;
    • Simmons, Gary;
    • Davis, James A.;
    • Kalariya, Nilesh;
    • Peres, Lauren C.
    Publication type:
    Article
    36

    Redefining attrition in multiple myeloma (MM): a Canadian Myeloma Research Group (CMRG) analysis.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00883-x
    By:
    • McCurdy, Arleigh;
    • Mian, Hira;
    • LeBlanc, Richard;
    • Jimenez-Zepeda, Victor H.;
    • Su, Jiandong;
    • Masih-Khan, Esther;
    • Visram, Alissa;
    • Louzada, Martha;
    • Song, Kevin;
    • White, Darrell;
    • Sebag, Michael;
    • Stakiw, Julie;
    • Reiman, Anthony;
    • Aslam, Muhammad;
    • Bergstrom, Debra;
    • Kotb, Rami;
    • Kaedbey, Rayan;
    • Gul, Engin;
    • Reece, Donna;
    • Venner, Christopher P.
    Publication type:
    Article
    37

    Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00887-7
    By:
    • Carobbio, Alessandra;
    • Vannucchi, Alessandro Maria;
    • Rumi, Elisa;
    • De Stefano, Valerio;
    • Rambaldi, Alessandro;
    • Carli, Giuseppe;
    • Randi, Maria Luigia;
    • Gisslinger, Heinz;
    • Passamonti, Francesco;
    • Thiele, Juergen;
    • Gangat, Naseema;
    • Tefferi, Ayalew;
    • Barbui, Tiziano
    Publication type:
    Article
    38
    39
    40

    Bortezomib, lenalidomide and dexamethasone (VRd) vs carfilzomib, lenalidomide and dexamethasone (KRd) as induction therapy in newly diagnosed multiple myeloma.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00882-y
    By:
    • Tan, Carlyn Rose;
    • Derkach, Andriy;
    • Nemirovsky, David;
    • Ciardiello, Amanda;
    • Diamond, Benjamin;
    • Hultcrantz, Malin;
    • Hassoun, Hani;
    • Mailankody, Sham;
    • Shah, Urvi;
    • Maclachlan, Kylee;
    • Patel, Dhwani;
    • Lahoud, Oscar B.;
    • Landau, Heather J.;
    • Chung, David J.;
    • Shah, Gunjan L.;
    • Scordo, Michael;
    • Giralt, Sergio A.;
    • Lesokhin, Alexander;
    • Usmani, Saad Z.;
    • Landgren, Ola
    Publication type:
    Article
    41
    42

    Nationwide prospective survey of secondary myelofibrosis in Japan: superiority of DIPSS-plus to MYSEC-PM as a survival risk model.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00869-9
    By:
    • Shide, Kotaro;
    • Takenaka, Katsuto;
    • Kitanaka, Akira;
    • Numata, Akihiko;
    • Kameda, Takuro;
    • Yamauchi, Takuji;
    • Inagaki, Atsushi;
    • Mizuno, Shohei;
    • Takami, Akiyoshi;
    • Ito, Shinichi;
    • Hagihara, Masao;
    • Usuki, Kensuke;
    • Maekawa, Takaaki;
    • Sunami, Kazutaka;
    • Ueda, Yasunori;
    • Tsutsui, Miyuki;
    • Ando, Miki;
    • Komatsu, Norio;
    • Ozawa, Keiya;
    • Kurokawa, Mineo
    Publication type:
    Article
    43
    44
    45
    46

    Targeting PP2A-dependent autophagy enhances sensitivity to ruxolitinib in JAK2<sup>V617F</sup> myeloproliferative neoplasms.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00875-x
    By:
    • Courdy, Charly;
    • Platteeuw, Loïc;
    • Ducau, Charlotte;
    • De Araujo, Isabelle;
    • Boet, Emeline;
    • Sahal, Ambrine;
    • Saland, Estelle;
    • Edmond, Valérie;
    • Tavitian, Suzanne;
    • Bertoli, Sarah;
    • Cougoul, Pierre;
    • Granat, Fanny;
    • Poillet, Laura;
    • Marty, Caroline;
    • Plo, Isabelle;
    • Sarry, Jean-Emmanuel;
    • Manenti, Stéphane;
    • Mansat-De Mas, Véronique;
    • Joffre, Carine
    Publication type:
    Article
    47

    Potential value of pre-planned imaging of bone disease in multiple myeloma.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00880-0
    By:
    • Gundesen, Michael T.;
    • Asmussen, Jon Thor;
    • Schjesvold, Fredrik;
    • Vangsted, Annette Juul;
    • Helleberg, Carsten;
    • Haukås, Einar;
    • Silkjær, Trine;
    • Teodorescu, Elena Manuela;
    • Jensen, Bo Amdi;
    • Slørdahl, Tobias S.;
    • Nahi, Hareth;
    • Waage, Anders;
    • Abildgaard, Niels;
    • Lund, Thomas
    Publication type:
    Article
    48
    49

    Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00862-2
    By:
    • Rapaport, Franck;
    • Seier, Kenneth;
    • Neelamraju, Yaseswini;
    • Hassane, Duane;
    • Baslan, Timour;
    • Gildea, Daniel T.;
    • Haddox, Samuel;
    • Lee, Tak;
    • Murdock, H. Moses;
    • Sheridan, Caroline;
    • Thurmond, Alexis;
    • Wang, Ling;
    • Carroll, Martin;
    • Cripe, Larry D.;
    • Fernandez, Hugo;
    • Mason, Christopher E.;
    • Paietta, Elisabeth;
    • Roboz, Gail J.;
    • Sun, Zhuoxin;
    • Tallman, Martin S.
    Publication type:
    Article
    50

    Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia.

    Published in:
    Blood Cancer Journal, 2023, v. 13, n. 1, p. 1, doi. 10.1038/s41408-023-00870-2
    By:
    • Hengeveld, P. J.;
    • Schilperoord-Vermeulen, J.;
    • van der Klift, M. Y.;
    • Dubois, J. M. N.;
    • Kolijn, P. M.;
    • Kavelaars, F. G.;
    • Rijken, M.;
    • Dobber, J. A.;
    • Nasserinejad, K.;
    • Kersting, S.;
    • Westerweel, P. E.;
    • Kater, A. P.;
    • Langerak, A. W.;
    • Levin, M-D.
    Publication type:
    Article